Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + sitravatinib vs docetaxel in NSCLC
CTR20211410Phase 3Terminated
- Sponsor
- BeiGene
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Jun 2021; status: terminated.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211410.